Pharmafocus March 2018 is available to read online now!
pharmafile | February 28, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Pharmafocus, brexit, drug safety, pharma, real world data
Though never truly out of vogue, the drug pricing debate has flared up again with the White House’s release of the white paper Reforming Biopharmaceutical Pricing at Home and Abroad. The report asserts that the United States’ healthcare bill – the largest in the world per capita by quite a margin – is due to inefficient regulation and foreign governments which demand universal healthcare and low prices for their citizens, leaving the US to foot the rest of the bill and allow manufacturers to see a return on their investments. You can read the full details on page 7.
All eyes have been on Greece as it emerges that 10 of its politicians, including former Prime Minister Antonis Samaras, stand accused of bribery and collusion with pharma giant Novartis. With the Greek parliament voting in favour of investigating the politicians in question, legal counter-action has been launched and the whole situation threatens to descend into farce. The full story can be found on page 6.
On page 12, we also have exclusive comment from Dr Paul Allen from the University of Roehampton on the remarkable findings unearthed by his institution and King’s College London, whereby schizophrenia patients demonstrated the ability to control auditory verbal hallucinations by using the team’s specially designed video game twinned with an MRI scanner.
Also don’t miss our features on drug safety, real world evidence, and a special head-to-head piece in which Catalyst Corporate Finance’s Tom Cowap and the Brexit Health Alliance’s Sarah Collen put forward their arguments on whether Brexit will be a disaster or big opportunity for the pharma and life sciences industries.
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
